155 related articles for article (PubMed ID: 36583111)
1. Efficacy and safety of cilostazol in decreasing progression of cerebral white matter hyperintensities-A randomized controlled trial.
Ip BYM; Lam BYK; Hui VMH; Au LWC; Liu MWT; Shi L; Lee VWY; Chu WCW; Leung TW; Ko H; Mok VCT
Alzheimers Dement (N Y); 2022; 8(1):e12369. PubMed ID: 36583111
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study.
Han SW; Song TJ; Bushnell CD; Lee SS; Kim SH; Lee JH; Kim GS; Kim OJ; Koh IS; Lee JY; Suk SH; Lee SI; Nam HS; Kim WJ; Lee KY; Park JH; Kim JY; Park JH
Cerebrovasc Dis; 2014; 38(3):197-203. PubMed ID: 25300977
[TBL] [Abstract][Full Text] [Related]
3. Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial.
Kim BC; Youn YC; Jeong JH; Han HJ; Kim JH; Lee JH; Park KH; Park KW; Kim EJ; Oh MS; Shim Y; Lee JM; Choi YH; Park G; Kim S; Park HY; Yoon B; Yoon SJ; Cho SJ; Park KC; Na DL; Park SA; Choi SH
Stroke; 2022 Mar; 53(3):698-709. PubMed ID: 34781708
[TBL] [Abstract][Full Text] [Related]
4. A Comparison Study of Cilostazol and Aspirin on Changes in Volume of Cerebral Small Vessel Disease White Matter Changes: Protocol of a Multicenter, Randomized Controlled Trial.
Han HJ; Kim BC; Youn YC; Jeong JH; Kim JH; Lee JH; Park KH; Park KW; Kim EJ; Oh MS; Shim YS; Park HY; Yoon B; Yoon SJ; Cho SJ; Park KC; Na DL; Park SA; Lee JM; Choi SH
Dement Neurocogn Disord; 2019 Dec; 18(4):138-148. PubMed ID: 31942173
[TBL] [Abstract][Full Text] [Related]
5. Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial.
Webb AJS; Birks JS; Feakins KA; Lawson A; Dawson J; Rothman AMK; Werring DJ; Llwyd O; Stewart CR; Thomas J
Circ Res; 2024 Jul; 135(2):320-331. PubMed ID: 38832504
[TBL] [Abstract][Full Text] [Related]
6. Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination.
Blair GW; Appleton JP; Law ZK; Doubal F; Flaherty K; Dooley R; Shuler K; Richardson C; Hamilton I; Shi Y; Stringer M; Boyd J; Thrippleton MJ; Sprigg N; Bath PM; Wardlaw JM
Int J Stroke; 2018 Jul; 13(5):530-538. PubMed ID: 28906205
[TBL] [Abstract][Full Text] [Related]
7. Quantitative and qualitative MRI evaluation of cerebral small vessel disease in an elderly population: a longitudinal study.
Nylander R; Fahlström M; Rostrup E; Kullberg J; Damangir S; Ahlström H; Lind L; Larsson EM
Acta Radiol; 2018 May; 59(5):612-618. PubMed ID: 28814098
[TBL] [Abstract][Full Text] [Related]
8. Only White Matter Hyperintensities Predicts Post-Stroke Cognitive Performances Among Cerebral Small Vessel Disease Markers: Results from the TABASCO Study.
Molad J; Kliper E; Korczyn AD; Ben Assayag E; Ben Bashat D; Shenhar-Tsarfaty S; Aizenstein O; Shopin L; Bornstein NM; Auriel E
J Alzheimers Dis; 2017; 56(4):1293-1299. PubMed ID: 28157096
[TBL] [Abstract][Full Text] [Related]
9. Cerebral Microbleeds and White Matter Hyperintensities are Associated with Cognitive Decline in an Asian Memory Clinic Study.
Gyanwali B; Lui B; Tan CS; Chong EJY; Vrooman H; Chen C; Hilal S
Curr Alzheimer Res; 2021; 18(5):399-413. PubMed ID: 34420506
[TBL] [Abstract][Full Text] [Related]
10. Confluent White Matter in Progression to Alzheimer Dementia.
Heng LC; Lim SH; Foo H; Kandiah N
Alzheimer Dis Assoc Disord; 2021 Jan-Mar 01; 35(1):8-13. PubMed ID: 33009038
[TBL] [Abstract][Full Text] [Related]
11. Imaging Markers of Subcortical Vascular Dementia in Patients With Multiple-Lobar Cerebral Microbleeds.
Lin CY; Jhan SR; Lee WJ; Chen PL; Chen JP; Chen HC; Chen TB
Front Neurol; 2021; 12():747536. PubMed ID: 34867731
[No Abstract] [Full Text] [Related]
12. White matter hyperintensities associated with progression of cerebral small vessel disease: a 7-year Chinese urban community study.
Xia Y; Shen Y; Wang Y; Yang L; Wang Y; Li Y; Liang X; Zhao Q; Wu J; Chu S; Liang Z; Wang X; Qiu B; Ding H; Ding D; Cheng X; Dong Q
Aging (Albany NY); 2020 May; 12(9):8506-8522. PubMed ID: 32388497
[TBL] [Abstract][Full Text] [Related]
13. Combined Score of Perivascular Space Dilatation and White Matter Hyperintensities in Patients with Normal Cognition, Mild Cognitive Impairment, and Dementia.
Zdanovskis N; Platkājis A; Kostiks A; Šneidere K; Stepens A; Naglis R; Karelis G
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888606
[No Abstract] [Full Text] [Related]
14. Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease.
Zeestraten EA; Lawrence AJ; Lambert C; Benjamin P; Brookes RL; Mackinnon AD; Morris RG; Barrick TR; Markus HS
Neurology; 2017 Oct; 89(18):1869-1876. PubMed ID: 28978655
[TBL] [Abstract][Full Text] [Related]
15. White Matter Cerebrovascular Reactivity: Effects of Microangiopathy and Proximal Occlusions on the Dynamic BOLD Response.
Gee JM; Wang X; Dogra S; Veraart J; Ishida K; Dehkharghani S
medRxiv; 2023 Jun; ():. PubMed ID: 37398412
[TBL] [Abstract][Full Text] [Related]
16. The association between lacunes and white matter hyperintensity features on MRI: The SMART-MR study.
Ghaznawi R; Geerlings MI; Jaarsma-Coes MG; Zwartbol MH; Kuijf HJ; van der Graaf Y; Witkamp TD; Hendrikse J; de Bresser J
J Cereb Blood Flow Metab; 2019 Dec; 39(12):2486-2496. PubMed ID: 30204039
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Kwan J; Hafdi M; Chiang LLW; Myint PK; Wong LS; Quinn TJ
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012269. PubMed ID: 35833913
[TBL] [Abstract][Full Text] [Related]
18. Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75 years of age.
Guo Y; Li Y; Liu X; Cui Y; Zhao Y; Sun S; Jia Q; Chai Q; Gong G; Zhang H; Liu Z
BMC Geriatr; 2020 Aug; 20(1):292. PubMed ID: 32807086
[TBL] [Abstract][Full Text] [Related]
19. Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial.
Blair GW; Appleton JP; Flaherty K; Doubal F; Sprigg N; Dooley R; Richardson C; Hamilton I; Law ZK; Shi Y; Stringer MS; Thrippleton MJ; Boyd J; Shuler K; Bath PM; Wardlaw JM
EClinicalMedicine; 2019; 11():34-43. PubMed ID: 31317131
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal white matter hyperintensity changes and cognitive decline in patients with minor stroke.
Jiang J; Yao K; Huang X; Zhang Y; Shen F; Weng S
Aging Clin Exp Res; 2022 May; 34(5):1047-1054. PubMed ID: 35084664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
